RWM
BDTX icon

Ritholtz Wealth Management’s Black Diamond Therapeutics BDTX Stock Holding History

Ritholtz Wealth Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Buy
178,479
+13,146
+8% +$32.2K ﹤0.01% 1007
2026
Q1 		$352K Sell
165,333
-62,537
-27% -$149K 0.01% 915
2025
Q4 		$554K Buy
227,870
+126,391
+125% +$448K 0.01% 688
2025
Q3 		$385K Buy
+101,479
New +$297K 0.01% 759

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Ritholtz Wealth Management's BDTX Position: Q2 2026 in Review

Ritholtz Wealth Management increased its Black Diamond Therapeutics (BDTX) stake by 8% in Q2 2026, buying an estimated $32.2K and bringing the position to 178,479 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Ritholtz Wealth Management first reported a position in BDTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $554K in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Ritholtz Wealth Management held 178,479 shares of Black Diamond Therapeutics worth $330K as of Q2 2026.
  • Ritholtz Wealth Management bought 13,146 Black Diamond Therapeutics shares in Q2 2026, an estimated $32.2K.
  • Black Diamond Therapeutics made up ﹤0.01% of Ritholtz Wealth Management's portfolio in Q2 2026, its #1007 holding.
  • Ritholtz Wealth Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Ritholtz Wealth Management's Black Diamond Therapeutics position peaked at $554K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.